ICU Medical, Inc. (ICUI) Stock Analysis
Falling Knife setup
Healthcare · Medical Instruments & Supplies
Sell if holding. Momentum 1.2/10 is below the 5.0 floor at $117.60 — engine's falling-knife protection flags exit rather than catching a breakdown. Specifics: Concentration risk — Supplier: single and limited source third-party suppliers; Earnings in 7 days (event risk).
ICU Medical develops and sells medical products for infusion therapy, vascular access, and vital care to hospitals, wholesalers, and alternate-site facilities in over 100 countries, with manufacturing in the US, Costa Rica, Mexico, and Czech Republic. A single major distributor... Read more
Sell if holding. Momentum 1.2/10 is below the 5.0 floor at $117.60 — engine's falling-knife protection flags exit rather than catching a breakdown. Specifics: Concentration risk — Supplier: single and limited source third-party suppliers; Earnings in 7 days (event risk). Chart setup: Death cross, below all MAs, RSI 36, MACD bearish. Score 4.5/10, moderate confidence.
Passes 4/7 gates (favorable risk/reward ratio, clean insider activity, no SEC red flags, semi cycle peak clear). Fails on weak momentum and death cross (50MA < 200MA) and earnings proximity 7d<=7d. Suitability: aggressive.
Thesis
Key Metrics
Quality Signals
Options Flow
Concentration Risks(10-K Item 1A)
- LOWCustomersingle distributor18%10-K Item 1A: 'we had worldwide net sales to a single distributor of 18%, 18%, and 16% of consolidated net sales, respectively.'
- HIGHSuppliersingle and limited source third-party suppliers10-K Item 1A: 'We are dependent on single and limited source third-party suppliers, which subjects our business and results of operations to risks of supplier business interruptions'
- MEDIUMGeographicMexico and Costa Rica10-K Item 1A: 'Significant changes in U.S. trade, tax or other policies that restrict imports or increase import tariffs for certain countries, particularly Mexico and Costa Rica'
Material Events(8-K, last 90d)
- 2026-02-20Item 5.02LOWICU Medical Compensation Committee approved an amendment to the Executive Severance Plan extending its expiration date by three years to December 31, 2028. No officer departure or appointment; compensatory arrangement modification only.SEC filing →
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. Full disclaimer
Rating Breakdown
3 floor-breakers
Revenue shrinking — -14.1% YoY. Growth thesis broken unless recovery story develops.static
Price action weak — below key moving averages, no momentum carry. Needs a base before trend-continuation setups apply.static
Ranks in the bottom of its industry peers on the composite signal. Better names in the same sector exist.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Sell if holding. Momentum 1.2/10 is below the 5.0 floor at $117.60 — engine's falling-knife protection flags exit rather than catching a breakdown. Specifics: Concentration risk — Supplier: single and limited source third-party suppliers; Earnings in 7 days (event risk). Chart setup: Death cross, below all MAs, RSI 36, MACD bearish. Prior stop was $109.97. Score 4.5/10, moderate confidence.
Take-profit target: $154.43 (+31.5% upside). Prior stop was $109.97. Stop-loss: $109.97.
Concentration risk — Supplier: single and limited source third-party suppliers; Earnings in 7 days (event risk); Weak overall score: 4.5/10.
ICU Medical, Inc. trades at a P/E of 3848.3 (forward 12.6). TrendMatrix value score: 8.3/10. Verdict: Sell.
12 analysts cover ICUI with a consensus score of 4.2/5. Average price target: $178.
What does ICU Medical, Inc. do?ICU Medical develops and sells medical products for infusion therapy, vascular access, and vital care to hospitals,...
ICU Medical develops and sells medical products for infusion therapy, vascular access, and vital care to hospitals, wholesalers, and alternate-site facilities in over 100 countries, with manufacturing in the US, Costa Rica, Mexico, and Czech Republic. A single major distributor accounted for 18% of consolidated 2025 net sales.